Neurodevelopmental Disorders Clinical Trial
Official title:
CYP2D6 PHARMACOGENETICS IN RISPERIDONE-TREATED CHILDREN AND ADOLESCENTS WITH PSYCHIATRIC OR NEURODEVELOPMENTAL DISORDERS
Risperidone is an important medication used to treat children with psychiatric illnesses or neurodevelopmental disorders, such as autism. Despite excellent symptom control, the potential for side effects is worrisome. Treating these disorders is difficult because not everyone responds the same way to the same risperidone dose. One reason for this is genetic differences in how people break down the drug. Understanding these differences will help clinicians choose a dose and better predict the response so patients will be treated successfully with a lower risk for side effects. This study will research these genetic differences in children with psychiatric or neurodevelopmental disorders. Hypothesis: The inter-patient variability in risperidone pharmacokinetics and exposure, adverse events, and clinical response in patients with psychiatric or neurodevelopmental disorders is associated with identifiable pharmacogenetic factors, such as CYP2D6 single nucleotide polymorphisms (SNPs).
Status | Completed |
Enrollment | 47 |
Est. completion date | June 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 3 Years to 18 Years |
Eligibility |
Inclusion Criteria: - Previous risperidone PK study participation (CCHMC, Rainbow Babies and Children's Hospital or OSU) - CYP2D6 PM predicted phenotype - Actively taking risperidone - Under 18 years of age at time of enrollment - Signed, dated informed consent forms Exclusion Criteria: - Investigators are unable to contact the subject/legal guardian(s) - Subject is no longer taking risperidone - CYP2D6 predicted phenotype other than PM - Subject is non-White, with respect to race, for PK study participation - Subject is 18 years of age or older - Subject is less than 5 years of age - Subject is pregnant at the time of the full PK study - Subject/legal guardian unwilling or unable to participate in the study |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
Lead Sponsor | Collaborator |
---|---|
Children's Hospital Medical Center, Cincinnati | Ohio State University, Rainbow Babies and Children's Hospital |
United States,
Aman MG, Vinks AA, Remmerie B, Mannaert E, Ramadan Y, Masty J, Lindsay RL, Malone K. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clin Ther. 2007 Jul;29(7):1476-86. — View Citation
Cabovska B, Cox SL, Vinks AA. Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):497-504. Epub 2007 Feb 15. — View Citation
Sherwin CM, Saldaña SN, Bies RR, Aman MG, Vinks AA. Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. Ther Drug Monit. 2012 Oct;34(5):535-44. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | association of common CYP2D6 polymorphisms with risperidone area under the curve | pre-dose (sample 1 = 0-30 minutes before first oral dose), and three at well-timed post-dose points (sample 2 = 15-30 minutes after dose; sample 3 = 60-90 minutes after dose; sample 4 = 4-6 hours after dose) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03148782 -
Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
|
N/A | |
Active, not recruiting |
NCT04935593 -
Strengthening Social, Emotional and Behavioral Resilience
|
N/A | |
Recruiting |
NCT03222375 -
SQUEDâ„¢ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
|
N/A | |
Completed |
NCT04313283 -
Translating Peer-to-Peer Support Into a Clinical Setting
|
N/A | |
Completed |
NCT04562935 -
Long-term Consequences of Admission for Pediatric Intensive Care Before One Year of Age
|
||
Not yet recruiting |
NCT05815095 -
Early Detection and Referral for Autism and Neurodevelopmental Disorders at the Maternal and Child Protection Services
|
||
Recruiting |
NCT05017363 -
Evaluation of the Effectiveness of Child-oriented Goal-setting in Paediatric Rehabilitation (the ENGAGE Approach)
|
N/A | |
Completed |
NCT06251830 -
Increasing Diagnosis Rates While Reducing Examination Time: Can MR Fingerprinting Deliver on Its Promise?
|
||
Completed |
NCT06052878 -
Neurodevelopmental Outcome After Prenatal Anesthesia
|
||
Recruiting |
NCT06012903 -
Lower Urinary Tract Symptoms and School Functioning in Children
|
||
Not yet recruiting |
NCT05490173 -
The Pilot Experimental Study of the Neuroprotective Effects of Exosomes in Extremely Low Birth Weight Infants
|
N/A | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Not yet recruiting |
NCT05564871 -
Effectiveness of Occupational Therapy Teleintervention in Pediatric
|
N/A | |
Enrolling by invitation |
NCT02871674 -
Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
|
N/A | |
Completed |
NCT01922791 -
Nutrition and Pregnancy Intervention Study
|
N/A | |
Active, not recruiting |
NCT05428657 -
EC Brain Program for Children With Special Education Needs
|
N/A | |
Recruiting |
NCT06111898 -
Neuro-biomechanical Determinants for Motor Behavior in High-risk Infants
|
||
Recruiting |
NCT05658965 -
KIDSHEART AND BRAIN : Early EEG Surgery Congenital Heart Disease Predict Onset of Neurodevelopmental Disorders
|
||
Recruiting |
NCT06086951 -
Pai.ACT - An Artificial Intelligence Driven Chatbot Assisted ACT
|
N/A | |
Recruiting |
NCT05997680 -
A Parent-child Yoga Intervention for Reducing Attention Deficits in Children With Congenital Heart Disease: A Feasibility Study
|
N/A |